Alimta News and Research

RSS
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

UK Court passes verdict in favor of Lilly relating to Alimta vitamin regimen patent claim

UK Court passes verdict in favor of Lilly relating to Alimta vitamin regimen patent claim

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Top performing oncology drugs at risk of losing patent rights by 2022

Top performing oncology drugs at risk of losing patent rights by 2022

Personalized treatment may be effective in wild type cancers

Personalized treatment may be effective in wild type cancers

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

OncoMed announces data from demcizumab preclinical study on pancreatic cancer

OncoMed announces data from demcizumab preclinical study on pancreatic cancer

Lilly announces final results from ALIMTA Phase III study on NSCLC

Lilly announces final results from ALIMTA Phase III study on NSCLC

Lilly to present oncology data from more than 25 studies at ASCO annual meeting

Lilly to present oncology data from more than 25 studies at ASCO annual meeting

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

African Americans more likely than Caucasians to develop and die from lung cancer

African Americans more likely than Caucasians to develop and die from lung cancer

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

New discovery can provide insight into lung cancer

New discovery can provide insight into lung cancer

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

TTF therapy with chemotherapy increases survival time in patients with non-small cell lung cancer

TTF therapy with chemotherapy increases survival time in patients with non-small cell lung cancer